---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-026146"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2026-03-11T23:59:59+00:00"
generated_at: "2026-05-15T14:43:54.631708+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sagimet Biosciences Reports 2025 Financial Results and MASH/Acne Program Updates

## Summary
- Cash and marketable securities $113.1M; net loss $51M for full year 2025.
- Completed Phase 1 PK trial of denifanstat+resmetirom; Phase 2 combo trial in F4 MASH expected 2H 2026.
- Exclusive license from TAPI for innovative resmetirom API forms to develop fixed-dose combination.
- Ascletis reported positive Phase 3 acne data for denifanstat; NDA accepted by China NMPA.
- Initiated Phase 1 trial of TVB-3567, a FASN inhibitor for acne.

## SEC filing metadata
- accession: 0001104659-26-026146
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2026-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465926026146/0001104659-26-026146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465926026146/tm268496d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-026146
- JSON: https://secwatch.observer/filing/0001104659-26-026146.json
- Plain text: https://secwatch.observer/filing/0001104659-26-026146.txt

## Key facts
- Earnings Releases
  Sagimet Biosciences Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Result: reported results
  source text: On March 11, 2026, Sagimet Biosciences Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1400118/000110465926026146/0001104659-26-026146-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.